Genmab's epcoritamab combo shows high response rates in trial for follicular lymphoma.

From Nasdaq: 2024-12-07 22:20:05

Genmab A/S released new data from a trial on epcoritamab for follicular lymphoma patients, showing a 96% overall response rate and an 87% complete response rate. The study also indicated an 80% progression-free survival rate at 21 months and a 90% overall survival rate at two years.

Further analysis revealed that 89% of complete responders were still in remission at 18 months. However, the study noted that COVID-19 affected 57% of patients, leading to discontinuation of epcoritamab in 13% of cases. Neutropenia and cytokine release syndrome were the most common adverse events reported, with most cytokine release syndrome events being low grade.



Read more at Nasdaq: Genmab : Epcoritamab Combo Shows High Response Rates In 1b/2 Trial For R/R Follicular Lymphoma